Skip to main content
SpringerLink
Log in

Laboratory Evaluation of Thrombophilia

  • Protocol
  • First Online:
Hemostasis and Thrombosis

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2663))

Abstract

Venous thromboembolism (VTE) occurs typically in the veins of the lower extremities and/or as pulmonary embolism. There is a myriad of causes of VTE ranging from provoked causes (e.g., surgery, cancer) to unprovoked causes (e.g., inherited abnormalities) or multiple factors that combine to initiate the cause. Thrombophilia is a complex, multi-factorial disease that may result in VTE. The mechanism(s) and causes of thrombophilia are complex and not completely understood. In healthcare today, only some answers about the pathophysiology, diagnosis, and prevention of thrombophilia have been elucidated. The laboratory analysis for thrombophilia is not consistently applied, and has changed over time, but remains varied by providers and laboratories as well. Both groups must establish harmonized guidelines for patient selection and appropriate conditions for analysis of inherited and acquired risk factors. This chapter discusses the pathophysiology of thrombophilia, and evidence-based medicine guidelines discuss the optimum laboratory testing algorithms and protocols for selection and analyzing VTE patients to ensure a cost-effective use of limited resources.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Christiansen S1C, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293:2352–2361

    Google Scholar 

  2. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemst 5:692–699

    Article  CAS  Google Scholar 

  3. Wendelboe AM, Raskob GE (2016) Global burden of thrombosis. Circ Res 118:1340–1347

    Article  CAS  PubMed  Google Scholar 

  4. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2016) Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation 133:e38–e360

    Google Scholar 

  5. Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, Bailey KR (2017) Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost 117:390–400

    Article  PubMed  Google Scholar 

  6. Eby C (2008) Laboratory diagnosis of inherited thrombophilia. In: Kottke-Marchant K (ed) An algorithmic approach to hemostasis testing. College of American pathologists, Northfield, Illinois, pp 267–277

    Google Scholar 

  7. Baglin T, Gray E, Greaves M et al (2010) Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 149:209–220

    Article  PubMed  Google Scholar 

  8. Johnson NV, Khor B, Van Cott EM (2012) Advances in laboratory testing for thrombophilia. Am J Hematol 87(Suppl 1):S108–S112

    Article  CAS  PubMed  Google Scholar 

  9. Coppens M, Reijnders JH, Middeldorp S, Doggen CJ, Rosendaal FR (2008) Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 6:1474–1477

    Article  CAS  PubMed  Google Scholar 

  10. Moll S (2014) New insights into treatment of venous thromboembolism. Hematology 2014. American Society of Hematology Education Program: American Society of Hematology, American Society of Hematology, pp 297–305

    Google Scholar 

  11. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I (2011) Risk factors for venous and arterial thrombosis. Blood Transfus 9:120–138

    PubMed  PubMed Central  Google Scholar 

  12. Somma J, Sussman II, Rand JH (2006) An evaluation of thrombophilia screening in an urban tertiary care medical center: A “real world” experience. Am J Clin Pathol 126:120–127

    Article  PubMed  Google Scholar 

  13. Martinelli I, Bucciarelli P, Mannucci PM, Mannucci M (2010) Thrombotic risk factors: basic pathophysiology. Crit Care Med 38(Suppl 2):S3–S9

    Article  PubMed  Google Scholar 

  14. Egeberg O (1965) Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13:516–530

    CAS  PubMed  Google Scholar 

  15. Seligsohn U, Lubetsky A (2001) Genetic susceptibility to venous thrombosis. N Engl J Med 344:1222–1231

    Article  CAS  PubMed  Google Scholar 

  16. Heit JA, Phelps MA, Ward SA, Slusser JP, Petterson TM, DeAndrade M (2004) Familial segregation of venous thromboembolism. J Thromb Haemost 2:731–736

    Article  CAS  PubMed  Google Scholar 

  17. Martinelli I, DeStefano V, Mannucci PM (2014) Inherited risk factors for venous thromboembolism. Nat Rev Cardiol 11:140–156

    Article  CAS  PubMed  Google Scholar 

  18. Marlar RA, Adcock DM, Madden RM (1990) Hereditary dysfunctional protein C molecules (type II): assay characterization and proposed classification. Thromb Haemost 63:375–379

    Article  CAS  PubMed  Google Scholar 

  19. Marciniak E, Wilson HD, Marlar RA (1985) Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood 65:15–20

    Article  CAS  PubMed  Google Scholar 

  20. Dahlback B (2008) Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 112:19–27

    Article  PubMed  Google Scholar 

  21. Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G (2006) Inherited thrombophilia. Crit Rev Clin Lab Sci 43:249–290

    Article  CAS  PubMed  Google Scholar 

  22. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GDO, Collins R, Danesh J (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367:651–658

    Article  CAS  PubMed  Google Scholar 

  23. Loundas G, Loundas KG (2017) Conceptual foundations of systems biology explaining complex cardiac diseases. Healthcare 5:10–28

    Article  Google Scholar 

  24. Koster T, Rosendaal FR, Briët E et al (1995) Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study). Blood 85:2756–2761

    Article  CAS  PubMed  Google Scholar 

  25. Marlar RA (2012) Are the laboratory results (phenotype) indicative of a true genotype abnormality? Am J Clin Pathol 137:173–175

    Article  CAS  PubMed  Google Scholar 

  26. Stevens SM, Woller SC, Bauer KA et al (2016) Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 41(1):154–164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Marlar RA (2001) The protein C system: how complex is it? Thromb Haemost 85:756–757

    Article  CAS  PubMed  Google Scholar 

  28. Lindstrom S, Wang L, Smith EN et al (2019) Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood 134:1645–1657

    Article  PubMed  PubMed Central  Google Scholar 

  29. Emmerich J, Rosendaal FR, Cattaneo M et al (2001) Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism—pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 86:809–816

    Article  CAS  PubMed  Google Scholar 

  30. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC (2001) A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 113:636–641

    Article  CAS  PubMed  Google Scholar 

  31. Moll S (2015) Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis 39:367–378

    Article  CAS  PubMed  Google Scholar 

  32. Iorio A, Kearon C, Filippucci E et al (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170:1710–1716

    Article  PubMed  Google Scholar 

  33. Lijfering WM, Middeldorp S, Veeger NJ et al (2010) Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 121:1706–1712

    Article  CAS  PubMed  Google Scholar 

  34. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ (2009) The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 169:610–615

    Article  PubMed  Google Scholar 

  35. Chong LY, Fenu E, Stansby G, Hodgkinson S (2012) Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. Br Med J 344:e3979

    Article  Google Scholar 

  36. van Vlijmen EF, Veeger NJ, Middeldorp S, Hamulyak K, Prins MH, Buller HR, Meijer K (2011) Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 118:2055–2061

    Article  PubMed  Google Scholar 

  37. Van den Broucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344:1453–1457

    Article  Google Scholar 

  38. Noboa S, Le Gal G, Lacut K et al (2008) Family history as a risk factor for venous thromboembolism. Thromb Res 122:624–629

    Article  CAS  PubMed  Google Scholar 

  39. Montagnana M, Favaloro EJ, Franchini M, Guidi GC, Lippi G (2010) The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis 29:489–496

    Article  PubMed  Google Scholar 

  40. Cushman M (2014) Thrombophilia testing in women with venous thrombosis: the 4 P’s approach. Clin Chem 60:134–137

    Article  CAS  PubMed  Google Scholar 

  41. Franchin M, Martinelli I, Mannucci PM (2016) Uncertain thrombophilia markers. Thromb Haemostas 115:25–30

    Article  Google Scholar 

  42. Kyrle PA, Minar E, Hirschl M et al (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343:457–462

    Article  CAS  PubMed  Google Scholar 

  43. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR (2000) High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis. N Engl J Med 342:696–701

    Article  CAS  PubMed  Google Scholar 

  44. Frischmuth T, Hindberg K, Aukrust P, Ueland T, Brækkan SK, Hansen JB, Morelli VM (2022) Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism. J Thromb Hemost 20:1618–1626

    Article  CAS  Google Scholar 

  45. Middeldorp S (2014) Anticoagulation in pregnancy complications. American Society of Hematology Education Program. Hematology 2014. American Society of Hematology Education Program: American Society of Hematology, Washington DC, pp 393–399

    Google Scholar 

  46. Le Gal G, Kovacs MJ, Carrier M et al (2010) Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost 104:498–503

    Article  PubMed  Google Scholar 

  47. Aldrighi JM, De Campos LS, Eluf Gebara OC, Petta CA, Bahamondes L (2006) Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 micro esgestodene on hemostatic parameters. Gynecol Endocrinol 22:1–4

    Article  CAS  PubMed  Google Scholar 

  48. Braekkan SK, Siegerink B, Lijfering WM, Hansen JB, Cannegieter SC, Rosendaal FR (2013) Role of obesity in the etiology of deep vein thrombosis and pulmonary embolism: current epidemiological insights. Semin Thromb Hemost 39:533–540

    Article  CAS  PubMed  Google Scholar 

  49. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ (2007) Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 139:289–296

    Article  PubMed  Google Scholar 

  50. Lijfering WM, Brouwer JL, Veeger NJ et al (2009) Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 113:5314–5322

    Article  CAS  PubMed  Google Scholar 

  51. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW (1994) Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 87:106–112

    Article  CAS  PubMed  Google Scholar 

  52. Segal JB, Brotman DJ, Necochea AJ et al (2009) Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 301:2472–2485

    Article  CAS  PubMed  Google Scholar 

  53. Mahmoodi BK, Brouwer JLP,Veeger NJGM, Van der Meer J (2008) Hereditary deficiency of protein C or protein S confer increased risk of arterial thromboembolic events at a young age. Results from a large family cohort study. Circulation 118:1659–1667

    Article  PubMed  Google Scholar 

  54. ten Kate MK, van deer Meer J (2008) Protein S deficiency: a clinical perspective. Haemophilia 14:1222–1228

    PubMed  Google Scholar 

  55. Ioannou HV, Mitsis M, Eleftheriou A, Matsagas M, Nousias V, Rigopoulos C (2000) The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of north-western Greece. Int Angiol 19:314–318

    CAS  PubMed  Google Scholar 

  56. Kim RJ, Becker RC (2003) Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146:948–957

    Article  CAS  PubMed  Google Scholar 

  57. Kovács B, Bereczky Z, Oláh Z et al (2013) The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency. Am J Clin Pathol 140:675–679

    Article  PubMed  Google Scholar 

  58. Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar RA (2020) Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. J Thromb Hemost 18:17–22

    Article  Google Scholar 

  59. Khor B, Van Cott EM (2010) Laboratory tests for antithrombin deficiency. Am J Hematol 85:947–950

    Article  PubMed  Google Scholar 

  60. Cooper P, Pavlova A, Moore GW, Hickey KP, Marlar RA (2020) Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH. J Thromb Hemostas 18:271–277

    Article  CAS  Google Scholar 

  61. Marlar RA, Gausman JN (2014) Laboratory testing issues for protein C, protein S, and antithrombin. Internat J Lab Hem 36:289–295

    Article  CAS  Google Scholar 

  62. Marlar RA, Gausman JN, Tsuda H, Rollin-Raval M, Brinkman HJ (2021) Guidance for clinical laboratory testing for protein S deficiency. J Thromb Hemostas 19:68–74

    Article  Google Scholar 

  63. Duebgen S, Kauke T, Marschall C et al (2012) Genotype and laboratory and clinical phenotypes of protein S deficiency. Am J Clin Pathol 137:178–184

    Article  CAS  PubMed  Google Scholar 

  64. Comp PC, Esmon CT (1984) Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311:1525–1528

    Article  CAS  PubMed  Google Scholar 

  65. Marlar RA, Gausman JN (2011) Protein S abnormalities: a diagnostic nightmare. Am J Hematol 86:418–421

    Article  CAS  PubMed  Google Scholar 

  66. Brinkman HJM, Ahnström J, Castoldi E, Dahlbäck B, Marlar RA (2021) Reclassification of Protein S deficiencies; keeping up with evolving knowledge. J Thromb Hemostas 19:281–286

    Article  CAS  Google Scholar 

  67. Johnston AM, Aboud M, Morel-Kopp MC, Coyle L, Ward CM (2007) Use of a functional assay to diagnose protein S deficiency; inappropriate testing yields equivocal results. Intern Med J 37:409–411

    Article  CAS  PubMed  Google Scholar 

  68. Dahlbäck B (2018) Vitamin K-dependent protein S: beyond the protein C pathway. Semin Thromb Hemost 44:176–184

    Article  PubMed  Google Scholar 

  69. Moore GW, Van Cott EM, Cutler JA, Mitchell MJ, Adcock DM (2019) Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH. J Hemostas Thromb 17:1555–1561

    Article  Google Scholar 

  70. Bertina RM, Koeleman BPC, Koster T (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67

    Article  CAS  PubMed  Google Scholar 

  71. Kadauke S, Khor B, Van Cott EM (2014) Activated protein C resistance testing for factor V Leiden. Am J Hematol 89:1147–1150

    Article  CAS  PubMed  Google Scholar 

  72. Poort SR, Rosendaal FR, Reitsma PM, Bertina RM (1996) A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703

    Article  CAS  PubMed  Google Scholar 

  73. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE (2007) Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 28:389–392

    Article  Google Scholar 

  74. Soria JM, Almasy L, Souto JC et al (2000) Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 95:2780–2785

    Article  CAS  PubMed  Google Scholar 

  75. McColl MD, Ramsay JE, Tait RC et al (1997) Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 78:1183–1188

    Article  CAS  PubMed  Google Scholar 

  76. Streiff MB (2013) Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients. Clin Adv Hematol Oncol 11:349–357

    PubMed  Google Scholar 

  77. Božič-Mijovski M (2010) Hyperhomocysteinemia and thrombophilia. Clin Chem Lab Med 48(Suppl 1):S89–S95

    PubMed  Google Scholar 

  78. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL, Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies (2014) Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 12:792–795

    Article  CAS  PubMed  Google Scholar 

  79. Devreese KM (2014) Antiphospholipid antibody testing and standardization. Int J Lab Hematol 36:352–363

    Article  CAS  PubMed  Google Scholar 

  80. Martinuzzo ME, Barrera LH, D’adamo MA, Otaso JC, Gimenez MI, Oyhamburu J (2014) Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol 36:144–150

    Article  CAS  PubMed  Google Scholar 

  81. Schulman S, Svenungsson E, Granqvist S (1998) Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104:332–338

    Article  CAS  PubMed  Google Scholar 

  82. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, and British Committee for Standards in Haematology (2012) Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 157:47–58

    Article  Google Scholar 

  83. Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G (2011) ‘Criteria’ aPL tests: report task force and preconference workshop at the 13th international congress on antiphospholipid antibodies, Galveston, Texas, April 2010. Lupus 20:182–190

    Article  CAS  PubMed  Google Scholar 

  84. Schneider-MacRae N, Jackson SC, Valentine KA, Lockyer J, Poon MC (2012) A study of thrombophilia testing and counseling practices of family physicians using the script concordance method in Calgary, Canada. Clin Appl Thromb Hemost 18:403–418

    Article  CAS  PubMed  Google Scholar 

  85. Cohn DM, Vansenne F, Kaptein AA, De Borgie CA, Middeldorp S (2008) The psychological impact of testing for thrombophilia: a systematic review. J Thromb Haemost 6:1099–1104

    Article  CAS  PubMed  Google Scholar 

  86. Wu O, Robertson L, Twaddle S et al (2006) Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 10:1–110

    Article  CAS  PubMed  Google Scholar 

  87. Smith TW, Pi D, Hudoba M, Lee AY (2014) Reducing inpatient heritable thrombophilia testing using a clinical decision-making tool. J Clin Pathol 67:345–349

    Article  PubMed  Google Scholar 

  88. Monagle P, Barnes C, Ignjatovic V et al (2006) Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 95:362–372

    Article  CAS  PubMed  Google Scholar 

  89. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L (1992) Maturation of the hemostatic system during childhood. Blood 80:1998–2005

    Article  CAS  PubMed  Google Scholar 

  90. Nowak-Göttl U, van Ommen H, Kenet G (2018) Thrombophilia testing in children: What and when should be tested? Thromb Res 164:75–78

    Article  PubMed  Google Scholar 

  91. Lippi G, Mattiuzzi C, Favaloro EJ (2014) Thrombophilia testing in patients taking direct oral anticoagulants. Handle with care Diagnosis 1:311–312

    PubMed  Google Scholar 

  92. Adcock DM, Gosselin R (2015) Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb Res 136:7–12

    Article  CAS  PubMed  Google Scholar 

  93. Adcock DM, Gosselin R, Kitchen S, Dwyre DM (2013) The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 139:102–109

    Article  CAS  PubMed  Google Scholar 

  94. Gosselin RC, Marlar RA (2019) Pre-analytical variables in coagulation testing: setting the stage for accurate results. Sem Thromb Hemost 45:433–448

    Article  Google Scholar 

  95. Kitchen S, Adcock DM, Dauer R et al (2021) International Council for Standardization in Hematology (ICSH) Recommendations for Collection of Blood Samples for Coagulation testing. Int J Lab Heme 43:571–580

    Article  Google Scholar 

  96. Kitchen S, Adcock DM, Dauer R et al (2021) International Council for Standardization in Hematology (ICSH) Recommendations for Processing of Blood Samples for Coagulation testing. Int J Lab Heme 43:1272–1283

    Article  Google Scholar 

  97. Garcia-Horton A, Kovacs MJ, Abdulrehman J, Taylor JE, Sharma S, Lazo-Langner A (2017) Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res 149:76–80

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of New Mexico, TriCore Reference Laboratories, Albuquerque, NM, USA

    Richard A. Marlar

Authors
  1. Richard A. Marlar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard A. Marlar .

Editor information

Editors and Affiliations

  1. School of Medical Sciences, Faculty of Medicine and Health University of Sydney, Westmead Hospital, Westmead, NSW, Australia

    Emmanuel J. Favaloro

  2. Hemostasis & Thrombosis Center, University of California, Davis, Sacramento, CA, USA

    Robert C. Gosselin

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Marlar, R.A. (2023). Laboratory Evaluation of Thrombophilia. In: Favaloro, E.J., Gosselin, R.C. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 2663. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3175-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-3175-1_10

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-3174-4

  • Online ISBN: 978-1-0716-3175-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation